MDGL, the stock of Madrigal Pharmaceuticals, has been showing signs of a bullish pattern since March 14, 2023. A Broadening Bottom pattern has emerged, which is a bullish reversal pattern. This pattern indicates that the stock has been undergoing increased volatility, with wider price swings, but is ultimately trending upwards.
This pattern was confirmed on April 24, 2023, when the stock broke out of the pattern's resistance level. The breakout was accompanied by strong volume, indicating that there was significant buying pressure, which is a positive sign for investors.
The current confidence level to reach the target price of 369.58 USD is 90%. This means that there is a high likelihood that the stock will reach this level in the near future. The distance to the target price is currently 21%, which represents a significant upside potential.
Investors who want to capitalize on this bullish pattern can consider the breakout price of 307.08 USD as an entry point. This is the price level at which the stock broke out of the pattern's resistance level and is therefore considered a strong buy signal.
The target (exit) price of 369.58 USD represents a potential gain of 20.3% from the breakout price. This is a significant return on investment and represents a good opportunity for investors who are looking to enter the market.
The Broadening Bottom pattern that has emerged in MDGL is a bullish reversal pattern that indicates the stock is trending upwards. The breakout of the pattern's resistance level on April 24, 2023, accompanied by strong volume, confirms this bullish trend. The current confidence level to reach the target price of 369.58 USD is high, and the distance to the target price represents a significant upside potential. Investors who are looking to capitalize on this trend can consider the breakout price of 307.08 USD as an entry point and set a target (exit) price of 369.58 USD.
The 10-day RSI Oscillator for MDGL moved out of overbought territory on May 01, 2023. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Momentum Indicator moved below the 0 level on May 25, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on MDGL as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MDGL turned negative on May 09, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .
MDGL moved below its 50-day moving average on June 01, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MDGL entered a downward trend on June 06, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.333) is normal, around the industry mean (25.217). P/E Ratio (0.000) is within average values for comparable stocks, (123.664). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.379). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (311.593).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases
|ETFs / NAME||Price $||Chg $||Chg %|
|ProShares UltraPro Short QQQ|
|First Trust Small Cap Val AlphaDEX® ETF|
|VanEck Vietnam ETF|
|Invesco BulletShares 2030 Muncpl Bd ETF|
|TrueShares Structured Outcome Dec ETF|
A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with SGMO. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then SGMO could also see price increases.
|SGMO - MDGL|
|VKTX - MDGL|
|IBRX - MDGL|
|KA - MDGL|
|RVMD - MDGL|